94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1586842
This article is part of the Research TopicAntibody-based Novel Target Immunotherapy in Hematological MalignancyView all articles
A potential prognostic marker for hematologic neoplasms: CD58
Provisionally accepted- Lanzhou University Second Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
CD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells. Aberrant expression of CD58 has been demonstrated to exert a significant impact on the prognosis of hematological tumors, including leukemia and lymphoma. Furthermore, this aberrant expression has been associated with drug resistance and immune rejection in CAR cell therapy. In this article, we will explore the future of CD58 in hematological oncology by describing its function in immune cells, its impact on hematological oncology and immunotherapies such as CAR cell therapy.
Keywords: biomarker, CD58 Antigens, CD2 Antigens, Immunological Synapses, Hematologic Neoplasms
Received: 03 Mar 2025; Accepted: 03 Apr 2025.
Copyright: © 2025 Cao, Zhang, Yue, Xiong, Zhang and Chongyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wu Chongyang, Lanzhou University Second Hospital, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.